14 Components Including RA Biologic, Oral Coagulant Drug Approved
This article was originally published in PharmAsia News
Executive Summary
Twenty-three new drug items made up of 14 components were approved by the Ministry of Health, Labor, and Welfare on Dec. 25.
Twenty-three new drug items made up of 14 components were approved by the Ministry of Health, Labor, and Welfare on Dec. 25. These included the biologic subcutaneous injection Cimzia for RA treatment (certolizumab) from UCB Japan, the oral coagulant Eliquis tablets (apixaban) from Bristol-Myers Squibb, and Choreazine (tetrabenazine), the first of its kind for treatment for Huntington’s disease in Japan, released by Alfresa. Other approved items were 4mg and 8mg Toviaz tablets from Pfizer Inc., 2mg and 3mg Afinitor tablets from Novartis AG, Allegra-D tablets from Sanofi, Malarone tables from GlaxoSmithKline PLC, 250mg Ameparomo capsules from Pfizer Inc., 2.25mg, 4.5mg, 9mg, 13.5mg Neupro Patch from Otsuka, Ryzodeg injection FlexTouch/Penfill from Novo Nordisk, 75mg Actonel tablets/75mg Benet tablets from Ajinomoto/Takeda, Phosribbon combination granules from Zeria, and 60μg Minirinmelt OD tablets from Ferring. (Click Here For More – Japanese Language)
“14 New Drug Components Approved Including RA Treatment Biologic And Oral Coagulant” mixonline.jp 12/26/2012